Current Oncology Reports

, Volume 14, Issue 3, pp 257–266

Management of Hepatocellular Carcinoma: Beyond Sorafenib

Gastrointestinal Cancers (L Saltz, Section Editor)

DOI: 10.1007/s11912-012-0233-0

Cite this article as:
Chan, S.L., Mok, T. & Ma, B.B.Y. Curr Oncol Rep (2012) 14: 257. doi:10.1007/s11912-012-0233-0


The positive results of sorafenib have unveiled a new direction of research in the management of hepatocellular carcinoma (HCC). Since then intensive efforts have been focused on development of novel management strategy to further improve the outcome for patients with HCC. Emerging data have suggested that tumor progression of HCC is driven by a number of deregulated signaling pathways and/or epigenetic mechanism. Thus much effort is dedicated to identification of novel agents targeting these dysregulated pathways. Combinations of targeted therapeutics and transarterial chemoembolization (TACE), or different systemic therapeutics also hold the promise to improve treatment outcome beyond sorafenib. This review aims to summarize the current status of clinical development of treatment in HCC. Perspectives on future direction of research will also be discussed.


Liver cancerTreatmentReviewBiologicGastrointestinal cancers

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Stephen L. Chan
    • 1
  • Tony Mok
    • 1
    • 2
  • Brigette B. Y. Ma
    • 1
  1. 1.State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales HospitalThe Chinese University of Hong KongShatinHong Kong
  2. 2.Department of Clinical OncologyThe Chinese University of Hong Kong, Prince of Wales HospitalShatinHong Kong